These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

692 related items for PubMed ID: 29314858

  • 1. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer.
    Aghevlian S, Lu Y, Winnik MA, Hedley DW, Reilly RM.
    Mol Pharm; 2018 Mar 05; 15(3):1150-1159. PubMed ID: 29314858
    [Abstract] [Full Text] [Related]

  • 2. Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to 177Lu.
    Aghevlian S, Cai Z, Lu Y, Hedley DW, Winnik MA, Reilly RM.
    Mol Pharm; 2019 Feb 04; 16(2):768-778. PubMed ID: 30589553
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(ab')2 alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib.
    Boyle AJ, Cao PJ, Cai Z, Chan C, Hedley DW, Reilly RM.
    Nucl Med Biol; 2020 Feb 04; 84-85():46-54. PubMed ID: 32062317
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Panitumumab-DOTA-111In: An Epidermal Growth Factor Receptor Targeted Theranostic for SPECT/CT Imaging and Meitner-Auger Electron Radioimmunotherapy of Triple-Negative Breast Cancer.
    Facca VJ, Cai Z, Gopal NEK, Reilly RM.
    Mol Pharm; 2022 Oct 03; 19(10):3652-3663. PubMed ID: 35926098
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Stability and Biodistribution of Thiol-Functionalized and (177)Lu-Labeled Metal Chelating Polymers Bound to Gold Nanoparticles.
    Yook S, Lu Y, Jeong JJ, Cai Z, Tong L, Alwarda R, Pignol JP, Winnik MA, Reilly RM.
    Biomacromolecules; 2016 Apr 11; 17(4):1292-302. PubMed ID: 26974228
    [Abstract] [Full Text] [Related]

  • 10. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
    Yook S, Cai Z, Lu Y, Winnik MA, Pignol JP, Reilly RM.
    Mol Pharm; 2015 Nov 02; 12(11):3963-72. PubMed ID: 26402157
    [Abstract] [Full Text] [Related]

  • 11. Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab')2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab')2 - implications for a PET theranostic strategy.
    Ku A, Kondo M, Cai Z, Meens J, Li MR, Ailles L, Reilly RM.
    EJNMMI Radiopharm Chem; 2021 Aug 12; 6(1):25. PubMed ID: 34383182
    [Abstract] [Full Text] [Related]

  • 12. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
    Boyle AJ, Cao PJ, Hedley DW, Sidhu SS, Winnik MA, Reilly RM.
    Nucl Med Biol; 2015 Feb 12; 42(2):71-7. PubMed ID: 25456837
    [Abstract] [Full Text] [Related]

  • 13. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with 177Lu.
    Cai Z, Yook S, Lu Y, Bergstrom D, Winnik MA, Pignol JP, Reilly RM.
    Pharm Res; 2017 Mar 12; 34(3):579-590. PubMed ID: 27987070
    [Abstract] [Full Text] [Related]

  • 14. Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses.
    Cheal SM, McDevitt MR, Santich BH, Patel M, Yang G, Fung EK, Veach DR, Bell M, Ahad A, Vargas DB, Punzalan B, Pillarsetty NVK, Xu H, Guo HF, Monette S, Michel AO, Piersigilli A, Scheinberg DA, Ouerfelli O, Cheung NV, Larson SM.
    Theranostics; 2020 Mar 12; 10(25):11359-11375. PubMed ID: 33052220
    [Abstract] [Full Text] [Related]

  • 15. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z, Ma T, Liu H, Jin Z, Sun X, Zhao H, Shi J, Jia B, Li F, Wang F.
    Mol Pharm; 2014 Mar 03; 11(3):800-7. PubMed ID: 24472064
    [Abstract] [Full Text] [Related]

  • 16. 64Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents.
    Kwon LY, Scollard DA, Reilly RM.
    Mol Pharm; 2017 Feb 06; 14(2):492-501. PubMed ID: 28049295
    [Abstract] [Full Text] [Related]

  • 17. Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten.
    Vaughn BA, Lee SG, Vargas DB, Seo S, Rinne SS, Xu H, Guo HF, Le Roux AB, Gajecki L, Krebs S, Yang G, Ouerfelli O, Zanzonico PB, Fung EK, St Jean S, Carrasco SE, Jungbluth A, Cheung NKV, Larson SM, Veach DR, Cheal SM.
    J Nucl Med; 2024 Oct 01; 65(10):1611-1618. PubMed ID: 39168519
    [Abstract] [Full Text] [Related]

  • 18. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates.
    Liu P, Boyle AJ, Lu Y, Adams J, Chi Y, Reilly RM, Winnik MA.
    Biomacromolecules; 2015 Nov 09; 16(11):3613-23. PubMed ID: 26469142
    [Abstract] [Full Text] [Related]

  • 19. Trastuzumab Labeled to High Specific Activity with (111)In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells.
    Ngo Ndjock Mbong G, Lu Y, Chan C, Cai Z, Liu P, Boyle AJ, Winnik MA, Reilly RM.
    Mol Pharm; 2015 Jun 01; 12(6):1951-60. PubMed ID: 25919639
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant Auger Electron-Emitting Radioimmunotherapy with [111In]In-DOTA-Panitumumab in a Mouse Model of Local Recurrence and Metastatic Progression of Human Triple-Negative Breast Cancer.
    Facca VJ, Cai Z, Ku A, Georgiou CJ, Reilly RM.
    Mol Pharm; 2023 Dec 04; 20(12):6407-6419. PubMed ID: 37983089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.